Bijou R Hunt1, Hollyn Cetrone2, Sharon Sam1, Nancy R Glick1,3. 1. 24192 Sinai Infectious Disease Center, Sinai Chicago, Chicago, IL, USA. 2. 12244 Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 3. 2473 Department of Medicine, Sinai Chicago, Chicago, IL, USA.
Abstract
OBJECTIVE: A recommendation in March 2020 to expand hepatitis C virus (HCV) screening to all adults in the United States will likely increase the need for HCV treatment programs and guidance on how to provide this service for diverse populations. We evaluated a pharmacist-led HCV treatment program within a routine screening program in an urban safety-net health system in Chicago, Illinois. METHODS: We collected data on all patient treatment applications submitted from January 1, 2017, through June 30, 2019, and assessed outcomes of and patient retention in the treatment cascade. RESULTS: During the study period, 203 HCV treatment applications were submitted for 187 patients (>1 application could be submitted per patient): 49% (n = 91) were aged 55-64, 62% (n = 116) were male, 67% (n = 125) were Black, and 15% (n = 28) were Hispanic. Of the 203 HCV treatment applications, 87% (n = 176) of patients were approved for treatment, 91% (n = 161) of whom completed treatment. Of the 161 patients who completed treatment, 81% (n = 131) attended their sustained virologic response (SVR) follow-up visit, 98% (n = 129) of whom reached SVR. The largest drop in the treatment cascade was the 19% decline from receipt of treatment to SVR follow-up visit. CONCLUSION: The pharmacist-led model for HCV treatment was effective in navigating patients through the treatment cascade and achieving SVR. Widespread implementation of pharmacist-led HCV treatment models may help to hasten progress toward 2030 HCV elimination goals.
OBJECTIVE: A recommendation in March 2020 to expand hepatitis C virus (HCV) screening to all adults in the United States will likely increase the need for HCV treatment programs and guidance on how to provide this service for diverse populations. We evaluated a pharmacist-led HCV treatment program within a routine screening program in an urban safety-net health system in Chicago, Illinois. METHODS: We collected data on all patient treatment applications submitted from January 1, 2017, through June 30, 2019, and assessed outcomes of and patient retention in the treatment cascade. RESULTS: During the study period, 203 HCV treatment applications were submitted for 187 patients (>1 application could be submitted per patient): 49% (n = 91) were aged 55-64, 62% (n = 116) were male, 67% (n = 125) were Black, and 15% (n = 28) were Hispanic. Of the 203 HCV treatment applications, 87% (n = 176) of patients were approved for treatment, 91% (n = 161) of whom completed treatment. Of the 161 patients who completed treatment, 81% (n = 131) attended their sustained virologic response (SVR) follow-up visit, 98% (n = 129) of whom reached SVR. The largest drop in the treatment cascade was the 19% decline from receipt of treatment to SVR follow-up visit. CONCLUSION: The pharmacist-led model for HCV treatment was effective in navigating patients through the treatment cascade and achieving SVR. Widespread implementation of pharmacist-led HCV treatment models may help to hasten progress toward 2030 HCV elimination goals.
Authors: Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson Journal: Hepatology Date: 2018-11-06 Impact factor: 17.425
Authors: Eduardo L Marino; Luis Alvarez-Rubio; Silvia Miro; Pilar Modamio; Fernando Banos; Cecilia F Lastra; Aintzane Alberdi-Leniz Journal: J Manag Care Pharm Date: 2009-03
Authors: Arlene C Seña; Sarah J Willis; Alison Hilton; Alexandria Anderson; David A Wohl; Christopher B Hurt; Andrew J Muir Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Alexander J Millman; Boatemaa Ntiri-Reid; Risha Irvin; Maggie H Kaufmann; Andrew Aronsohn; Jeffrey S Duchin; John D Scott; Claudia Vellozzi Journal: Top Antivir Med Date: 2017 Jul/Aug
Authors: Anil G Suryaprasad; Jianglan Z White; Fujie Xu; Beth-Ann Eichler; Janet Hamilton; Ami Patel; Shadia Bel Hamdounia; Daniel R Church; Kerri Barton; Chardé Fisher; Kathryn Macomber; Marisa Stanley; Sheila M Guilfoyle; Kristin Sweet; Stephen Liu; Kashif Iqbal; Rania Tohme; Umid Sharapov; Benjamin A Kupronis; John W Ward; Scott D Holmberg Journal: Clin Infect Dis Date: 2014-08-11 Impact factor: 9.079
Authors: Rima A Mohammad; Marilyn N Bulloch; Juliana Chan; Paulina Deming; Bryan Love; Lisa Smith; Betty J Dong Journal: Pharmacotherapy Date: 2014-10-31 Impact factor: 4.705
Authors: Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Katrina Donahue; Chyke A Doubeni; John W Epling; Martha Kubik; Gbenga Ogedegbe; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2020-03-10 Impact factor: 56.272